logo
Share SHARE
FONT-SIZE Plus   Neg

Impax Labs. Introduces Oxymorphone Hydrochloride Extended-Release Tablets

Impax Laboratories Inc.(IPXL) said it is commencing shipment of Oxymorphone Hydrochloride Extended-Release Tablets, via. Global Pharmaceuticals, Impax's generics unit.

In June 2010, Impax inked a deal with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle U.S. patent litigation concerning the production and sale of its Oxymorphone Hydrochloride Extended-Release Tablets approved by the U.S. Food and Drug Administration as therapeutically equivalent to the original formulation of OPANA ER. According to the settlement, Endo agreed to grant Impax a license to sell Impax's approved product on January 1, 2013.

Impax also noted that it is actively participating in efforts to support prescriber and patient education of this product through the FDA-approved Risk Evaluation and Mitigation Strategy. Oxymorphone Hydrochloride Extended-Release Tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Microsoft Corp. (MSFT) has cut the price of Xbox One bundles by $50 ahead of next month's Electronic Entertainment Expo. The 500GB Xbox One bundled with either Quantum Break, Gears of War: Ultimate Edition, The Lego Movie Videogame, Forza Motorsport 6, Rise of the Tomb Raider, or Rare Replay is now... Red-hot Las Vegas beat other big cities to become the best and most budget-friendly summer travel destination this year, according to financial website WalletHub. WalletHub's Shares of Allergan plc rose in early trades Tuesday after billionaire investor Carl Icahn said he recently acquired a "large position" in the Botox maker and was very supportive of CEO Brent Saunders. Icahn did not disclose details of the stake he acquired in Allergan.
comments powered by Disqus
Follow RTT